Patent · US Active

Pyrimidine compound acting on EGFR and ERBB2

US11530196B2 · kind B2 · utility

0Cited by

1References

7Claims

0Family size

Assignee

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED · CN

Inventors

Charles Z. Ding · San Mateo, US
Lu Zhang · Singapore, SG
Xile LIU · Shanghai, CN
Lihong Hu · Shanghai, CN
Wen Jiang · Shanghai, CN
Jian Li · Shanghai, CN
Shuhui CHEN · Shanghai, CN

Key dates

Filing date	Jul 24, 2020
Grant date	Dec 20, 2022
Priority date	—
Expiry date	Jul 24, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.